NEWS
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -
- The Company is currently discussing partnership opportunities to advance development of DMT410 -
- In 2022, the Japanese prevalence of hyperhidrosis was 10%, with approximately 6% having primary axillary hyperhidrosis -
SAN DIEGO, CA / ACCESSWIRE / January 4, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled "Compositions for the treatment of skin conditions," (Japanese Patent No. 7395576) further strengthens Dermata's intellectual property for DMT410 for the treatment of hyperhidrosis and could lead to further protections for additional indications.
"We believe this patent issuance further validates DMT410's novel concept to easily deliver botulinum toxin topically instead of requiring patients to receive multiple injections," says Gerry Proehl, Dermata's Chairman, President, and CEO. "We are excited about the opportunities the DMT410 program can bring to patients, not only for the treatment of axillary hyperhidrosis as we have seen in our proof-of-concept study, but potentially for palmer and plantar hyperhidrosis which has no currently approved products. We also believe there are opportunities to use DMT410 to treat many aesthetic skin conditions like reducing pore number and size, decreasing sebum production, and reducing fine lines and wrinkles, all while improving the look and quality of facial skin," continued Mr. Proehl. "We also believe this new patent could aid us in our partnership discussions with a company that has a botulinum toxin to further develop the DMT410 program for multiple indications."
About DMT410
